Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROS study of low-dose deferasirox in adults with sickle cell disease
NL-OMON49517Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in sickle cell disease (SCD), sickle cell anemia (SCA) and Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and Point of Sickling. Started Jul 2021; status: recruiting.
02
Drugs
deferasirox
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia)
Beyond the preview
Go deeper on NL-OMON49517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49517.